Continuous dopaminergic stimulation and novel formulations of dopamine agonists
- First Online:
- Cite this article as:
- Stocchi, F. J Neurol (2011) 258(Suppl 2): 316. doi:10.1007/s00415-011-6024-y
- 229 Downloads
There is now accumulating evidence that the combination of progressive pathology of Parkinson’s disease, the change in drug pharmacodynamics, and the pulsatile manner in which short-acting dopaminergic agents stimulate striatal dopamine receptors are the key contributing factors to the priming of the basal ganglia for induction of motor complications. Long-acting drugs provide a more physiological dopaminergic stimulation. Dopamine agonists have been extensively used as monotherapy and add-on therapy to levodopa to treat Parkinson’s disease in the early stage and with motor complications. Today, the new long-acting formulation offers the advantages of an easy use and a more continuous delivery of drug. In this paper the role of new formulations of dopamine agonists in the treatment of parkinsonian patients at different stages of the disease is reviewed.